As collagen, along with other extracellular matrix components, plays a key role in tumour growth and progression [2], it is not surprising that LAIR-1, an inhibitory receptor that recognizes collagen, presents itself as a promising target for cancer immunotherapy in multiple recent studies [3, 4, 27, 44, 45]. Here, LAIR1 is linked to cancer.